The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Open accessAbstract
BACKGROUND: The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2). METHODS: We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast cancer and a germline BRCA1/2 mutation were assigned, in a 2:1 ratio, to receive talazoparib (1 mg once daily) or standard single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles). The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the talazoparib group than in the standard-therapy group (8.6 months vs. 5.6 months; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001). The interim median hazard ratio for death was 0.76 (95% CI, 0.55 to 1.06; P=0.11 [57% of projected events]). The objective response rate was higher in the talazoparib group than in the standard-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001). Hematologic grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received standard therapy; nonhematologic grade 3 adverse events occurred in 32% and 38% of the patients, respectively. Patient-reported outcomes favored talazoparib; significant overall improvements and significant delays in the time to clinically meaningful deterioration according to both the global health status-quality-of-life and breast symptoms scales were observed. CONCLUSIONS: Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single-agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival. Patient-reported outcomes were superior with talazoparib. (Funded by Medivation [Pfizer]; EMBRACA ClinicalTrials.gov number, NCT01945775 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“At a median follow-up of 11.2 months, PFS was longer in the talazoparib arm (8.6 versus 5.6 months, HR 0.54; 95% CI 0.41-0.71, P < 0.0001).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 3,013
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A. N. J., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazińska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 909
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 895
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J. J., Takeda, S., Morris, J., Teicher, B. A., Doroshow, J. H., & Pommier, Y. G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 777
Repeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 519
Flagged first, then by citations
Research works printed but not linked: 1
- Turner NC, Telli ML, Rugo HS, et al. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). Presented at the American Society of Clinical Oncology 2017 Annual Meeting, Chicago, June 2–6, 2017. abstract.
Cited by
Sorted by citations
Items 601–700 of 1,000
Mantilla, W. A., Sanabria‐Salas, M. C., Baldión, A. M., Sua, L. F., Gonzalez, D. M., & Lema, M. (2021) · JCO Global Oncology · doi:10.1200/go.21.00046 · Cited by 25
Liu, Y. L., & Stadler, Z. K. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7044 · Cited by 25
Sun, X., Wang, X., Zhang, J., Zhao, Z., Feng, X., Liu, L., & Ma, Z. (2021) · The Breast · doi:10.1016/j.breast.2021.08.009 · Cited by 25
Penetrance of male breast cancer susceptibility genes: a systematic review
Chamseddine, R. S., Wang, C., Yin, K., Wang, J., Singh, P., Zhou, J., Robson, M. E., Braun, D., & Hughes, K. S. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06413-2 · Cited by 26
Targeting cancer stem cells in the tumor microenvironment: An emerging role of PARP inhibitors
Paul, S., Sinha, S., & Kundu, C. N. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106425 · Cited by 26
Evolving DNA repair synthetic lethality targets in cancer
Kulkarni, S., Brownlie, J., Jeyapalan, J. N., Mongan, N. P., Rakha, E. A., & Madhusudan, S. (2022) · Bioscience Reports · doi:10.1042/bsr20221713 · Cited by 27
The Challenges of Treating Patients with Breast Cancer and Obesity
LeVee, A. A., & Mortimer, J. E. (2023) · Cancers · doi:10.3390/cancers15092526 · Cited by 27
Rossi, A., Aimar, G., Audisio, M., Bungaro, M., Caglio, A., Liello, R. D., Gamba, T., Gargiulo, P., Ghisoni, E., Lombardi, P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.008 · Cited by 27
Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
Carvalho, F. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1244781 · Cited by 26
Balmañà, J., Fasching, P. A., Couch, F. J., Delaloge, S., Labidi‐Galy, S. I., O’Shaughnessy, J., Park, Y. H., Eisen, A. F., You, B., Bourgeois, H., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07165-x · Cited by 26
Self-citationScott, D., Friedman, S. J., Telli, M. L., & Kurian, A. W. (2019) · JCO Oncology Practice · doi:10.1200/jop.19.00221 · Cited by 25
Toss, A., Molinaro, E., Venturelli, M., Domati, F., Marcheselli, L., Piana, S., Barbieri, E., Grandi, G., Piombino, C., Marchi, I., et al. (2020) · Cancers · doi:10.3390/cancers12051252 · Cited by 25
A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors
Chehade, C. H., Gebrael, G., Sayegh, N., Özay, Z. İ., Narang, A., Crispino, T., Golan, T., Litton, J. K., Swami, U., Moore, K. N., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21870 · Cited by 28
Self-citationPedretti, F., Abdalfttah, M., Pellegrino, B., Mateo, F., Martínez-Sanz, P., Herencia-Ropero, A., Òdena, A., Clavell-Revelles, P., Casali, G., Domènech, H., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2531 · Cited by 28
Huynh, M.-M., Pambid, M. R., Jayanthan, A., Dorr, A., Los, G., & Dunn, S. E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1818067 · Cited by 23
Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
Clark, C. A., & Yang, E. S.-H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703802 · Cited by 24
Pacheco-Barcía, V., Martín, A. J. M., Castro, E., Ballesteros, A. I., Marquina, G., González-Díaz, I., Colomer, R., & Romero-Laorden, N. (2022) · Cancers · doi:10.3390/cancers14122950 · Cited by 23
Poddar, A., Rao, S. R., Prithviraj, P., Kannourakis, G., & Jayachandran, A. (2022) · Current Oncology · doi:10.3390/curroncol29100540 · Cited by 24
Huo, Y., Shao, S., Liu, E., Li, J., Tian, Z., Wu, X., Zhang, S., Stover, D. G., Wu, H., Cheng, L., et al. (2022) · Cancers · doi:10.3390/cancers14194878 · Cited by 24
Gupta, T., Vinayak, S., & Telli, M. L. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06780-4 · Cited by 24
How I treat endocrine-dependent metastatic breast cancer
Gombos, A., Gonçalvès, A., Curigliano, G., Bartsch, R., Kyte, J., Ignatiadis, M., & Awada, A. H. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100882 · Cited by 25
SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
García-Sáenz, J. Á., Blancas, I., Echavarría, I., Hinojo, C., Vila, M. M., Moreno, F., Pernas, S., y Cajal, T. R., Ribelles, N., & Bellet, M. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03203-8 · Cited by 26
Miyashita, M., Bell, J. S. K., Wenric, S., Karaesmen, E., Rhead, B., Kase, M., Kaneva, K., Vega, F. M. D. L., Zheng, Y., Yoshimatsu, T. F., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01627-2 · Cited by 25
Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer
Li, J., Goh, E. L. K., He, J., Li, Y., Fan, Z., Yu, Z., Yuan, P., & Liu, D. (2023) · Biology · doi:10.3390/biology12050697 · Cited by 27
Shi, M., Li, Z., Shen, G., Wang, T., Li, J., Wang, M., Liu, Z., Zhao, F., Ren, D., & Zhao, J. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.06.002 · Cited by 24
Emerging treatment approaches for triple-negative breast cancer
Capuozzo, M., Celotto, V., Santorsola, M., Fabozzi, A., Landi, L., Ferrara, F., Borzacchiello, A., Granata, V., Sabbatino, F., Savarese, G., et al. (2023) · Medical Oncology · doi:10.1007/s12032-023-02257-6 · Cited by 25
Pascual, T., González‐Farré, B., Teixidó, C., Oleaga, L., Oses, G., Ganau, S., Chic, N., Riu-Viladoms, G., Adamo, B., Galván, P., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00012 · Cited by 24
Jia, Y., Jin, H., Gao, L., Xiang, Y., Wang, F., Ding, H., Chen, A., Tan, S., Zhang, F., Shao, J., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15186 · Cited by 24
Zeng, C., Guo, X., Wen, W., Shi, J., Long, J., Cai, Q., Shu, X., Xiang, Y., & Zheng, W. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05643-0 · Cited by 24
Chen, X., Yang, D., Carey, J. P. W., Karakaş, C., Albarracin, C. T., Şahin, A. A., Arun, B., Durak, M. G., Li, M., Kohansal, M., et al. (2021) · Cancers · doi:10.3390/cancers13071656 · Cited by 25
Orsi, G., Marco, M. D., Cavaliere, A., Niger, M., Bozzarelli, S., Giordano, G., Noventa, S., Rapposelli, I. G., Garajová, I., Tortora, G., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100238 · Cited by 24
Antibody-Drug Conjugates in Triple Negative Breast Cancer
Keskinkılıç, M., & Sacks, R. L. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.01.008 · Cited by 26
Breast Cancer: Molecular Pathogenesis and Targeted Therapy
Samad, M. A., Ahmad, I., Khan, M. R., Suhail, M., Zughaibi, T. A., Al-Abbasi, F. A., Alhosaini, K. A., Khan, M. S., Kumer, A., & Tabrez, S. S. M. (2025) · MedComm · doi:10.1002/mco2.70404 · Cited by 28
Differential gene expression and AKT targeting in triple negative breast cancer
Lin, F., Yost, S. E., Wen, W. X., Frankel, P. H., Schmolze, D. D., Chu, P. G., Yuan, Y., Liu, Z., Yim, J. H., Chen, Z., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27026 · Cited by 23
Clinical Trials in Metastatic Uveal Melanoma: Current Status
Sussman, T. A., Funchain, P., & Singh, A. D. (2020) · Ocular Oncology and Pathology · doi:10.1159/000508383 · Cited by 23
Franzoi, M. A., Saúde-Conde, R., Cristóvão‐Ferreira, S., Eiger, D., Awada, A. H., & de Azambuja, E. (2021) · The Breast · doi:10.1016/j.breast.2021.03.002 · Cited by 23
Eustace, A. J., Lee, M. J., Colley, G., Roban, J., Downing, T., & Buchanan, P. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.41 · Cited by 22
PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications
Wang, X., Zeng, X., Li, D., Zhu, C., Guo, X., Feng, L., & Yu, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113458 · Cited by 24
Galland, L., Roussot, N., Desmoulins, I., Mayeur, D., Kaderbhaï, C., Ilie, S. M., Hennequin, A., Réda, M., Albuisson, J., Arnould, L., et al. (2023) · Cancers · doi:10.3390/cancers15041299 · Cited by 23
An overview of the research progress of BRCA gene mutations in breast cancer
Wan, A., Zhang, G., Ma, D., Zhang, Y., & Qi, X. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188907 · Cited by 25
Altena, R., Tzortzakakis, A., af Burén, S., Tran, T. A., Frejd, F. Y., Bergh, J. C. S., & Axelsson, R. (2023) · EJNMMI Research · doi:10.1186/s13550-023-00995-2 · Cited by 24
Egelston, C. A., Guo, W., Yost, S. E., Ge, X., Lee, J. S., Frankel, P. H., Cui, Y., Ruel, C., Schmolze, D. D., Murga, M., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03470-y · Cited by 24
Park, S., Kim, Y. J., Min, Y. J., Mortimer, P. G. S., Kim, H., Smith, S. A., Dean, E. J., Jung, H. A., Sun, J., Park, W., et al. (2023) · Cancer · doi:10.1002/cncr.35059 · Cited by 23
Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)
Xu, B., & Ma, F. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.12.001 · Cited by 24
Rao, X., Qiao, Z., Yang, Y., Deng, Y., Zhang, Z., Yu, X., & Guo, X. (2024) · Pharmaceuticals · doi:10.3390/ph17020225 · Cited by 24
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Chacón, J. I., de la Cruz‐Merino, L., Gregori, J. G., de Dueñas, E. M., Oliveira, M., Seguí, M. Á., Álvarez, I., Antolín, S., Bellet, M., & López‐Tarruella, S. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02010-w · Cited by 24
Simmons, C. E., Brezden‐Masley, C., McCarthy, J. S., McLeod, D., & Joy, A. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920909091 · Cited by 23
PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias
Fritz, C. E., Portwood, S. M., Przespolewski, A., & Wang, E. S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100696 · Cited by 23
Pouptsis, A., Swafe, L., Patwardhan, M., & Stavraka, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.553080 · Cited by 23
Comprehensive analysis of DNA damage repair deficiency in 10,284 pan–cancer study
Xiao, Y., Lu, D., Lei, M., Xie, W., Chen, Y., Zheng, Y., Wang, C., Zhao, J., Zhu, Z., Zhao, X., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-5449 · Cited by 22
Targeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy
Erebor, J. O., Agboluaje, E. O., Perkins, A. M., Krishnakumar, M., & Ngwuluka, N. C. (2024) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2024.046 · Cited by 22
Impact of Molecular Profiling on Therapy Management in Breast Cancer
Ultimescu, F., Hudiță, A., Popa, D. E., Olincă, M., Muresean, H. A., Ceaușu, M. C., Stanciu, D. I., Ginghină, O., & Gălățeanu, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13174995 · Cited by 25
Liquid biopsy in breast cancer: Redefining precision medicine
Schiavone, M. L., Scarpitta, R., Ravera, F., Bleve, S., Reduzzi, C., Cocco, F., Dameri, M., Zoppoli, G. M., Naccarato, A. G., Nuzzo, P. V., et al. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100312 · Cited by 22
Sambade, M. J., Swearingen, A. E. D. V., McClure, M. B., Deal, A. M., Santos, C., Sun, K., Wang, J., Mikule, K. W., & Anders, C. K. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz005 · Cited by 22
Delving into PARP inhibition from bench to bedside and back
Grignani, G., Merlini, A., Sangiolo, D., D’Ambrosio, L., & Pignochino, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107446 · Cited by 22
Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease
Bednarek, A. M., Mykała‐Cieśla, J., Pogoda, K., Jagiełło-Gruszfeld, A., Kunkiel, M., Winder, M., & Chudek, J. T. (2020) · Journal of Oncology · doi:10.1155/2020/7267083 · Cited by 22
Updates in Neoadjuvant Therapy for Triple Negative Breast Cancer
Tufano, A. M., Teplinsky, E., & Landry, C. A. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.07.001 · Cited by 22
Huang, R. S. P., Li, X., Haberberger, J., Sokol, E. S., Severson, E. A., Duncan, D. L., Hemmerich, A. C., Edgerly, C. I., Williams, E. A., Elvin, J. A., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0449 · Cited by 22
Kurian, A. W., Abrahamse, P. H., Bondarenko, I., Hamilton, A. S., Deapen, D., Gomez, S. L., Morrow, M., Berek, J. S., Hofer, T. P., Katz, S. J., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab151 · Cited by 22
Xu, J., Keenan, T. E., Overmoyer, B. A., Tung, N., Gelman, R. S., Habin, K. R., Garber, J. E., Ellisen, L. W., Winer, E. P., Goss, P. E., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06292-7 · Cited by 22
A review on mechanisms of resistance to PARP inhibitors
Desai, C. J., Pathak, A. B., Limaye, S. A., Maniar, V., & Joshi, A. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_53_21 · Cited by 23
Greco, S., Fabbri, N., Spaggiari, R., Giorgi, A. D., Fabbian, F., & Giovine, A. (2023) · Biomedicines · doi:10.3390/biomedicines11061772 · Cited by 21
Bottosso, M., Mosele, F., Michiels, S., Cournède, P.-H., Doğan, S., Labaki, C., & André, F. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102247 · Cited by 23
Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders
Faraoni, I., Giansanti, M., Voso, M. T., Lo‐Coco, F., & Graziani, G. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.019 · Cited by 23
Cseh, A. M., Fábián, Z., Quintana–Cabrera, R., Szabó, A., Erős, K., Soriano, M. E., Gallyas, F., Scorrano, L., & Sümegi, B. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00538 · Cited by 24
Rate of BRCA mutation in patients tested under NCCN genetic testing criteria
Beck, A. C., Yuan, H., Liao, J., Imperiale, P., Shipley, K., Erdahl, L. M., Sugg, S. L., Weigel, R. J., & Lizarraga, I. M. (2019) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2019.06.012 · Cited by 22
Ademuyiwa, F. O., Salyer, P., Ma, Y., Fisher, S. L., Colditz, G. A., Weilbaecher, K. N., & Bierut, L. J. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05359-w · Cited by 22
Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
Küemmel, S., Harrach, H., Schmutzler, R. K., Kostara, A., Ziegler-Löhr, K., Dyson, M. H., Chiari, O., & Reinisch, M. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00174-9 · Cited by 23
Wang, J., Zhang, Y., Yuan, L., Ren, L., Zhang, Y., & Qi, X. (2020) · Aging · doi:10.18632/aging.202152 · Cited by 22
Wang, Q., Zhang, F., Gao, H., & Xu, Y. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-113 · Cited by 22
Bao, S., Yue, Y., Hua, Y., Zeng, T., Yang, Y., Yang, F., Yan, X., Sun, C., Yang, M., Fu, Z., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1883 · Cited by 22
Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer
Haque, M., Shyanti, R. K., & Mishra, M. K. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1431418 · Cited by 25
Cognitive dysfunction in chemobrain: Molecular mechanisms and therapeutic implications
Kim, H., Rashid, M. A., Poleschuk, M., Ullah, F., Lee, S., Kim, S., Qin, B., Zheng, X., & Jang, M.-H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118581 · Cited by 25
Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
Boussios, S., Moschetta, M., Karihtala, P., Samartzis, E. P., Sheriff, M., Pappas‐Gogos, G., Öztürk, M. A., Uccello, M., Karathanasi, A., Tringos, M., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.156 · Cited by 21
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations
Layman, R. M., & Arun, B. K. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000499 · Cited by 22
Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
Chen, Z., Wang, X., Li, X., Zhou, Y., & Chen, K. (2021) · Journal of International Medical Research · doi:10.1177/0300060521991019 · Cited by 21
Marcheteau, E., Farge, T., Pérès, M., Labrousse, G., Tenet, J., Delmas, S., Chusseau, M., Duprez-Paumier, R., Franchet, C., Dalenc, F., et al. (2021) · Cancers · doi:10.3390/cancers13164059 · Cited by 23
Blum, J. L., Laird, A. D., Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Martin, M., Roche, H. H., Lee, K.-H., Goodwin, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2080 · Cited by 21
Self-citationHeitmeir, B., Deniz, M., Janni, W., Rack, B. K., Schochter, F., & Wiesmüller, L. (2022) · Cancers · doi:10.3390/cancers14040997 · Cited by 23
Piccolo, S., Mecham, A., Golightly, N. P., Johnson, J. L., & Miller, D. B. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009926 · Cited by 23
Beniey, M., Hubert, A., Haque, T., Cotte, A. K., Béchir, N., Zhang, X., Tran‐Thanh, D., & Hassan, S. N. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02226-w · Cited by 25
Targeting DNA damage repair precision medicine strategies in cancer
Brownlie, J., Kulkarni, S., Algethami, M., Jeyapalan, J. N., Mongan, N. P., Rakha, E. A., & Madhusudan, S. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102381 · Cited by 22
Mai, N., Abuhadra, N. K., & Jhaveri, K. L. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.05.012 · Cited by 24
Batalini, F., Madison, R. W., Sokol, E. S., Jin, D. X., Chen, K., Decker, B. J., Pavlick, D. C., Frampton, G. M., Wulf, G. M., Garber, J. E., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00091 · Cited by 25
Nicolini, A., & Ferrari, P. (2024) · Cancers · doi:10.3390/cancers16020466 · Cited by 23
A Phase 1 Mass Balance Study of 14C‐Labeled Talazoparib in Patients With Advanced Solid Tumors
Yu, Y., Chung, C., Plotka, A., Quinn, K. P., Shi, H., Pápai, Z., Nguyen, L. T., & Wang, D. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1415 · Cited by 21
Li, P., Zhen, Y., & Yu, Y. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.06.024 · Cited by 20
Biliary tract cancer prognostic and predictive genomics
Mondaca, S., Nervi, B., Pinto, M. P., & Abou‐Alfa, G. K. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.07.06 · Cited by 22
What’s the Price? Toxicities of Targeted Therapies in Breast Cancer Care
Anders, C. K., LeBoeuf, N. R., Bashoura, L., Faiz, S. A., Shariff, A. I., & Thomas, A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279465 · Cited by 21
Malhotra, H., Kowtal, P., Mehra, N., Pramank, R., Sarin, R., Rajkumar, T., Gupta, S., Bapna, A., Bhattacharyya, G. S., Gupta, S., et al. (2020) · JCO Global Oncology · doi:10.1200/jgo.19.00381 · Cited by 22
Kaito, S., & Iwama, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010074 · Cited by 21
A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer
Mo, H., Jazieh, K., Brinzevich, D., & Abraham, J. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.05.014 · Cited by 21
Gao, Y. K., Kuksis, M., Said, B. I., Chehade, R., Kiss, A., Tran, W. T., Sickandar, F., Sahgal, A., Warner, E., Soliman, H., et al. (2021) · The Oncologist · doi:10.1002/onco.13965 · Cited by 21
Divide and Conquer—Targeted Therapy for Triple-Negative Breast Cancer
Nedeljković, M., Vuletić, A. M., & Martinović, K. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041396 · Cited by 21
Shah, B. A., Hussain, M. S., & Seth, A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080638 · Cited by 28
Nadesh, R., Menon, K. N., Biswas, L., Mony, U., Iyer, K. S., Vijayaraghavan, S., Nambiar, A., & Nair, S. V. (2021) · Scientific Reports · doi:10.1038/s41598-021-01878-z · Cited by 21
Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer
Torregrosa, M. D., Barco, S. D., Cotes, A., Roso, L. L., Servitja, S., & Sarrió, R. G. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02766-8 · Cited by 22
Functional roles of ADP-ribosylation writers, readers and erasers
Li, P., Lei, Y., Jia, Q., Liu, W., & Yao, K. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.941356 · Cited by 20
Goel, S., Tan, A. R., Rugo, H. S., Aftimos, P. G., Andric, Z. G., Beelen, A. P., Zhang, J., Yi, J. S., Malik, R. K., & O’Shaughnessy, J. (2022) · Future Oncology · doi:10.2217/fon-2022-0773 · Cited by 20
Self-citationValenza, C., Rizzo, G., Passalacqua, M. I., Boldrini, L., Corti, C., Trapani, D., & Curigliano, G. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221146129 · Cited by 23
Metadata
- Authors
- Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., Roché, H., Im, Y.-H., Quek, R. G. W., Markova, D., Tudor, I. C., Hannah, A. L., Eiermann, W., & Blum, J. L.
- Affiliations
- Kaiser Permanente (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) — both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) — all in California; the...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-23
- Volume
- 379
- Issue
- 8
- Pages
- 753-763
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10600918
- OpenAlex
- W2886477543
- Cited by
- 2,175
- References
- 14
- Citations by year
- 2026: 195 · 2025: 241 · 2024: 254 · 2023: 312 · 2022: 356 · 2021: 319 · 2020: 280 · 2019: 195 · 2018: 20
- FWCI
- 76.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- PARP inhibitors, advanced breast cancer, germline BRCA1 mutation, germline BRCA2 mutation, progression-free survival, objective response rate, hematologic adverse events, anemia, patient-reported outcomes, quality of life, single-agent chemotherapy, capecitabine, eribulin, gemcitabine, vinorelbine, PARP inhibitor resistance, PARP inhibitor combination therapy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Patient Reported Outcome Measures, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Middle Aged, Phthalazines, Quality of Life, Survival Analysis, Germ-Line Mutation, Disease-Free Survival, Genes, BRCA1, Genes, BRCA2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
